Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | AGXT | P21549 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16485634 | 0.87 | HTT (0.56) | ALDH1A1HTTMAPTCA1CA2 | |
| SCHEMBL22759520 | 0.85 | HTT (0.57) | ALDH1A1HTTMAPTCA1CA2 | |
| SCHEMBL29105149 | 0.83 | RAB9A (0.54) | ALDH1A1MAPTCA1CA2NPC1 | |
| SCHEMBL7364455 | 0.81 | IDO1 (0.53) | ALDH1A1HTTMAPTCA1CA2 | |
| SCHEMBL4706402 | 0.81 | HTT (0.56) | ALDH1A1HTTMAPTCA1CA2 | |
| SCHEMBL2494898 | 0.80 | HTT (0.73) | ALDH1A1HTTMAPTCA1CA2 | |
| SCHEMBL1171808 | 0.80 | RAB9A (0.51) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19002576 | 0.80 | HTT (0.53) | ALDH1A1HTTMAPTCA1CA2 | |
| SCHEMBL5434584 | 0.80 | ALDH1A1 (0.63) | ALDH1A1HTTMAPTCA1CA2 | |
| SCHEMBL7720191 | 0.80 | HTT (0.53) | ALDH1A1HTTMAPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486890-A | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117486888-A | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-113966336-B | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-3980424-A1 | TRICYCLIC COMPOUNDS AND THEIR USE | Hutchison Medipharma Limited (CN) | 2022-04-13 | — | — | EP | disclosed |
| US-7320994-B2 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1501809-B1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1501809-A1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091226-A1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
| US-4427590-A | Triazolobenzodiazepine derivatives | CIBA-GEIGY CORPORATION (US) | 1984-01-24 | — | — | US | disclosed |
| US-4155913-A | ANTICONBULSANTS, MUSCLE RELAXANTS AND SEDATIVES | HOFFMANN-LA ROCHE INC. (US) | 1979-05-22 | — | — | US | disclosed |
| US-3941799-A | 6-Substituted-11b-phenyl-3, 11bH-oxazirino[2,3-d]-s-triazol[4,3-a][1,4]benzodiazepines | CIBA-GEIGY CORPORATION (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | TACR1, TACR2, BDKRB1 | ALDH1A1 1408/4885HTT 1628/4885MAPT 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.